secukinumab vs vunakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline
secukinumab · Cosentyx
Marketed by Novartis
NCT01392326 · Phase 3 · completed
In this large (n=606), randomized, quadruple-blind, placebo-controlled Phase 3 trial in active psoriatic arthritis, significantly more patients achieved an ACR20 response at week 24 on secukinumab 75 mg (50.5%) or 150 mg (50.0%) than on placebo (17.3%), a statistically significant difference for both doses (p<0.0001).
Next expected readout: October 2029 · NCT06751238 (registry estimate)
Reported efficacy
Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 (Baseline, Week 28): HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. (met)
Result source: NCT04632927
vunakizumab
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT05055934 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Proportion of subjects achieving ACR 20 improvement at week 12: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively (met)
Result source: NCT05055934
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | secukinumab | vunakizumab |
|---|---|---|
| ACR20 | 51% vs 15.3%+35.7 vs placeboNCT0175263417 other results
| —Trial running · NCT06640257 |
| ACR50 | 31.4% vs 6.3%+25 vs placeboNCT0420920513 other results
| —Trial running · NCT06640257 |
| PASI 75 | 48.3% vs 16.3%+32 vs placeboNCT0175263410 other results
| —Trial running · NCT06640257 |
| Minimal disease activity | 22.4% vs 5.3%+17.2 vs placeboNCT042092051 other result
| —Trial running · NCT06640257 |
| HAQ-DI, change | -0.5 vs -0.3−0.2 vs placeboNCT0175263412 other results
| —Trial running · NCT06640257 |
ACR20
- secukinumab
- 51% vs 15.3%+35.7 vs placeboNCT01752634
17 other results
- 42% vs 16.1% NCT01989468
- 59.5% vs 27.4% NCT02404350
- 55.5% vs 27.4% NCT02404350
- 41.2% vs 18.4% NCT02294227
- 39.8% vs 18.4% NCT02294227
- 54% vs 15.3% NCT01752634
- 48.2% vs 16.1% NCT01989468
- 62.6% vs 27.4% NCT02404350
- 29.3% vs 15.3% NCT01752634
- 70% vs 28.6% NCT04711902
- 67.4% vs 61.5% NCT02745080
- 67.5% vs 31.3% NCT02662985
- 56.5% vs 18.5% NCT02721966
- 28.9% vs 19.3% NCT02294227
- 23% vs 19.3% NCT02294227
- 51.6% vs 18.5% NCT02721966
- 59.6% vs 29.0% NCT04209205
- vunakizumab
- —Trial running · NCT06640257
ACR50
- secukinumab
- 31.4% vs 6.3%+25 vs placeboNCT04209205
13 other results
- 35% vs 7.1% NCT01752634
- 18.8% vs 8.8% NCT01989468
- 32% vs 8.1% NCT02404350
- 35.9% vs 8.1% NCT02404350
- 22.8% vs 6.1% NCT02294227
- 16.8% vs 6.1% NCT02294227
- 45.8% vs 8.4% NCT02662985
- 35% vs 7.1% NCT01752634
- 34.5% vs 8.8% NCT01989468
- 39.6% vs 8.1% NCT02404350
- 18.2% vs 7.1% NCT01752634
- 15% vs 4.8% NCT04711902
- 49% vs 44.8% NCT02745080
- vunakizumab
- —Trial running · NCT06640257
PASI 75
- secukinumab
- 48.3% vs 16.3%+32 vs placeboNCT01752634
10 other results
- 50% vs 10.2% NCT01989468
- 58.1% vs 12.3% NCT02404350
- 60% vs 12.3% NCT02404350
- 52.7% vs 8.1% NCT02294227
- 50% vs 8.1% NCT02294227
- 63.4% vs 16.3% NCT01752634
- 46.8% vs 10.2% NCT01989468
- 70% vs 12.3% NCT02404350
- 28% vs 16.3% NCT01752634
- 60.7% vs 46% NCT04632927
- vunakizumab
- —Trial running · NCT06640257
Minimal disease activity
- secukinumab
- 22.4% vs 5.3%+17.2 vs placeboNCT04209205
1 other result
- 35.7% vs 22.2% NCT04632927
- vunakizumab
- —Trial running · NCT06640257
HAQ-DI, change
- secukinumab
- -0.5 vs -0.3−0.2 vs placeboNCT01752634
12 other results
- -0.3 vs -0.2 NCT01989468
- -0.5 vs -0.2 NCT02404350
- -0.4 vs -0.2 NCT02404350
- -0.3 vs -0.2 NCT02721966
- -0.6 vs -0.3 NCT01752634
- -0.4 vs -0.2 NCT01989468
- -0.6 vs -0.2 NCT02404350
- -0.4 vs -0.2 NCT02721966
- -0.3 vs -0.3 NCT01752634
- -0.4 vs 0.1 NCT04209205
- -0.3 vs 0.1 NCT04711902
- -0.6 vs -0.6 NCT02745080
- vunakizumab
- —Trial running · NCT06640257
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. secukinumab: 4 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | secukinumab |
|---|---|
| Dropout rate | —150 mga NCT01392326 · Phase 3 show 46 more results—75 mg NCT01392326 · Phase 3 5%150 mg s.c. NCT01752634 · Phase 3 3%300 mg s.c. NCT01752634 · Phase 3 6.1%75 mg s.c. NCT01752634 · Phase 3 0%Secukinumab NCT04632927 · Phase 3 —Secukinumab - Entire Study NCT04632927 · Phase 3 —Secukinumab- On-Treatment NCT04632927 · Phase 3 — NCT03031782 · Phase 3 2.7%150 mg with load NCT02404350 · Phase 3 6.8%150 mg without load NCT02404350 · Phase 3 2.7%300 mg with load NCT02404350 · Phase 3 —150 mg NCT02798211 · Phase 4 · registry result, not featured evidence —300 mg NCT02798211 · Phase 4 · registry result, not featured evidence —150 mg NCT03769168 · Phase 3 · registry result, not featured evidence 66.7%150 mg NCT03769168 · Phase 3 · registry result, not featured evidence —300 mg NCT03769168 · Phase 3 · registry result, not featured evidence —75 mg NCT03769168 · Phase 3 · registry result, not featured evidence 47.4%75 mg NCT03769168 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence 0%150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —300 mg NCT04711902 · Phase 3 · registry result, not featured evidence —6 mg/kg - 3 mg/kg i.v NCT04209205 · Phase 3 · registry result, not featured evidence 9.4%6 mg/kg - 3 mg/kg i.v. NCT04209205 · Phase 3 · registry result, not featured evidence 1.2%150 mg + 300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —150+300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —300 mg NCT02745080 · Phase 3 · registry result, not featured evidence 12.9%300 mg s.c. NCT02745080 · Phase 3 · registry result, not featured evidence 10.8% NCT02771210 · Phase 3 · registry result, not featured evidence 13.9%150 mg NCT02721966 · Phase 3 · registry result, not featured evidence —150 mg NCT02721966 · Phase 3 · registry result, not featured evidence 17.4%300 mg NCT02721966 · Phase 3 · registry result, not featured evidence —300 mg NCT02721966 · Phase 3 · registry result, not featured evidence 34.1%150 mg NCT01989468 · Phase 3 · registry result, not featured evidence 26.6%300 mg NCT01989468 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 18.7%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 18%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —300 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 14.9%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 15.6%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 21.9%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence 22.1%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT01169844 · Phase 2 · registry result, not featured evidence 10.7%2x 10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence —2x10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —150 mga NCT01392326 · Phase 3 show 46 more results—75 mg NCT01392326 · Phase 3 0%150 mg s.c. NCT01752634 · Phase 3 2%300 mg s.c. NCT01752634 · Phase 3 3%75 mg s.c. NCT01752634 · Phase 3 0%Secukinumab NCT04632927 · Phase 3 —Secukinumab - Entire Study NCT04632927 · Phase 3 —Secukinumab- On-Treatment NCT04632927 · Phase 3 — NCT03031782 · Phase 3 0.9%150 mg with load NCT02404350 · Phase 3 0.9%150 mg without load NCT02404350 · Phase 3 1.4%300 mg with load NCT02404350 · Phase 3 —150 mg NCT02798211 · Phase 4 · registry result, not featured evidence —300 mg NCT02798211 · Phase 4 · registry result, not featured evidence —150 mg NCT03769168 · Phase 3 · registry result, not featured evidence 2.8%150 mg NCT03769168 · Phase 3 · registry result, not featured evidence —300 mg NCT03769168 · Phase 3 · registry result, not featured evidence —75 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%75 mg NCT03769168 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —300 mg NCT04711902 · Phase 3 · registry result, not featured evidence —6 mg/kg - 3 mg/kg i.v NCT04209205 · Phase 3 · registry result, not featured evidence 1%6 mg/kg - 3 mg/kg i.v. NCT04209205 · Phase 3 · registry result, not featured evidence 0%150 mg + 300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —150+300 mg NCT02662985 · Phase 3 · registry result, not featured evidence —300 mg NCT02745080 · Phase 3 · registry result, not featured evidence 3.1%300 mg s.c. NCT02745080 · Phase 3 · registry result, not featured evidence 4.9% NCT02771210 · Phase 3 · registry result, not featured evidence 2.4%150 mg NCT02721966 · Phase 3 · registry result, not featured evidence —150 mg NCT02721966 · Phase 3 · registry result, not featured evidence 2.4%300 mg NCT02721966 · Phase 3 · registry result, not featured evidence —300 mg NCT02721966 · Phase 3 · registry result, not featured evidence 7.2%150 mg NCT01989468 · Phase 3 · registry result, not featured evidence 10.8%300 mg NCT01989468 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 4%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 3.7%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —300 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 2.7%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 4.8%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence 5.3%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence 7.1%150 mg NCT02294227 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT01169844 · Phase 2 · registry result, not featured evidence —2x 10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence —2x10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 17.3%150 mga NCT01392326 · Phase 3 show 46 more results11%75 mg NCT01392326 · Phase 3 —150 mg s.c. NCT01752634 · Phase 3 —300 mg s.c. NCT01752634 · Phase 3 —75 mg s.c. NCT01752634 · Phase 3 —Secukinumab NCT04632927 · Phase 3 7.1%Secukinumab - Entire Study NCT04632927 · Phase 3 5.4%Secukinumab- On-Treatment NCT04632927 · Phase 3 14.6% NCT03031782 · Phase 3 4.1%150 mg with load NCT02404350 · Phase 3 2.7%150 mg without load NCT02404350 · Phase 3 3.2%300 mg with load NCT02404350 · Phase 3 3.9%150 mg NCT02798211 · Phase 4 · registry result, not featured evidence 7.9%300 mg NCT02798211 · Phase 4 · registry result, not featured evidence 9.3%150 mg NCT03769168 · Phase 3 · registry result, not featured evidence —150 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%300 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%75 mg NCT03769168 · Phase 3 · registry result, not featured evidence —75 mg NCT03769168 · Phase 3 · registry result, not featured evidence 0%150 mg NCT04711902 · Phase 3 · registry result, not featured evidence —150 mg NCT04711902 · Phase 3 · registry result, not featured evidence 4.8%300 mg NCT04711902 · Phase 3 · registry result, not featured evidence 5.9%6 mg/kg - 3 mg/kg i.v NCT04209205 · Phase 3 · registry result, not featured evidence —6 mg/kg - 3 mg/kg i.v. NCT04209205 · Phase 3 · registry result, not featured evidence —150 mg + 300 mg NCT02662985 · Phase 3 · registry result, not featured evidence 5.6%150+300 mg NCT02662985 · Phase 3 · registry result, not featured evidence 8.7%300 mg NCT02745080 · Phase 3 · registry result, not featured evidence —300 mg s.c. NCT02745080 · Phase 3 · registry result, not featured evidence 6.9% NCT02771210 · Phase 3 · registry result, not featured evidence —150 mg NCT02721966 · Phase 3 · registry result, not featured evidence 5.7%150 mg NCT02721966 · Phase 3 · registry result, not featured evidence —300 mg NCT02721966 · Phase 3 · registry result, not featured evidence 5.6%300 mg NCT02721966 · Phase 3 · registry result, not featured evidence —150 mg NCT01989468 · Phase 3 · registry result, not featured evidence —300 mg NCT01989468 · Phase 3 · registry result, not featured evidence 20.3%150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence —150 mg NCT01892436 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01892436 · Phase 3 · registry result, not featured evidence 16.4%75 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence —75 mg NCT01892436 · Phase 3 · registry result, not featured evidence —150 mg NCT02294227 · Phase 3 · registry result, not featured evidence —150 mg NCT02294227 · Phase 3 · registry result, not featured evidence 26.3%3 mg/kg NCT01169844 · Phase 2 · registry result, not featured evidence —2x 10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence 14.3%2x10mg/kg NCT00809614 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 150 mga upper respiratory tract infection 20.3% (placebo 5.9%) nasopharyngitis 18.3% (placebo 5.4%) headache 8.5% (placebo 3.5%) NCT01392326 · Phase 3 show 25 more results75 mg nasopharyngitis 20.9% (placebo 5.4%) upper respiratory tract infection 17.8% (placebo 5.9%) back pain 9.9% (placebo 1%) NCT01392326 · Phase 3 nasopharyngitis 33.3% (placebo 28.9%) diarrhoea 22.9% (placebo 15.8%) nausea 22.9% (placebo 21.1%) NCT03031782 · Phase 3 150 mg with load upper respiratory tract infection 7.7% (placebo 3.3%) viral upper respiratory tract infection 6.8% (placebo 8.7%) pruritus 5% (placebo 1.2%) NCT02404350 · Phase 3 150 mg without load upper respiratory tract infection 6.3% (placebo 3.3%) viral upper respiratory tract infection 5.9% (placebo 8.7%) hypertension 4.1% (placebo 3%) NCT02404350 · Phase 3 300 mg with load viral upper respiratory tract infection 6.3% (placebo 8.7%) diarrhoea 4.1% (placebo 6.6%) bronchitis 3.6% (placebo 0.6%) NCT02404350 · Phase 3 150 mg back pain 7.8% (placebo 15.4%) diarrhoea 6.8% (placebo 3.8%) hypertension 5.8% (placebo 0%) NCT02798211 · Phase 4 · registry result, not featured evidence 300 mg upper respiratory tract infection 13.6% (placebo 1.9%) diarrhoea 5.8% (placebo 3.8%) back pain 5.2% (placebo 15.4%) NCT02798211 · Phase 4 · registry result, not featured evidence 150 mg covid-19 20.9% nasopharyngitis 18.6% pain in extremity 18.6% NCT03769168 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 25% arthralgia 18.8% covid-19 18.8% NCT03769168 · Phase 3 · registry result, not featured evidence 75 mg arthralgia 21.1% abdominal pain upper 15.8% back pain 10.5% NCT03769168 · Phase 3 · registry result, not featured evidence 150 mg hyperlipidaemia 20% (placebo 38.1%) hypercholesterolaemia 16.7% (placebo 0%) hyperuricaemia 16.7% (placebo 9.5%) NCT04711902 · Phase 3 · registry result, not featured evidence 300 mg covid-19 23.8% (placebo 0%) hyperuricaemia 19% (placebo 9.5%) hyperlipidaemia 14.3% (placebo 38.1%) NCT04711902 · Phase 3 · registry result, not featured evidence 6 mg/kg - 3 mg/kg i.v covid-19 9.9% (placebo 3.7%) urinary tract infection 4.5% (placebo 0.5%) arthralgia 3.7% (placebo 1.6%) NCT04209205 · Phase 3 · registry result, not featured evidence 150+300 mg nasopharyngitis 11.8% (placebo 4.8%) headache 8.1% (placebo 3.6%) urinary tract infection 6.2% (placebo 3.6%) NCT02662985 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 20.7% upper respiratory tract infection 9.9% headache 8.5% NCT02745080 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.7% diarrhoea 7.8% arthralgia 6.9% NCT02771210 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 9% (placebo 6.6%) upper respiratory tract infection 5.7% (placebo 3%) pharyngitis 5.3% (placebo 3%) NCT02721966 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.7% (placebo 6.6%) diarrhoea 6.5% (placebo 2.4%) upper respiratory tract infection 4.8% (placebo 3%) NCT02721966 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 21.4% (placebo 5.4%) upper respiratory tract infection 19.2% (placebo 5.9%) headache 8.9% (placebo 3.5%) NCT01892436 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 8.5% (placebo 5.4%) upper respiratory tract infection 6.1% (placebo 5.9%) bronchitis 5.5% (placebo 3%) NCT01892436 · Phase 3 · registry result, not featured evidence 75 mg nasopharyngitis 24% (placebo 5.4%) upper respiratory tract infection 21.2% (placebo 5.9%) headache 10.6% (placebo 3.5%) NCT01892436 · Phase 3 · registry result, not featured evidence 3 mg/kg nasopharyngitis 36.8% (placebo 44.4%) arthralgia 26.3% (placebo 22.2%) oropharyngeal pain 26.3% (placebo 33.3%) NCT01169844 · Phase 2 · registry result, not featured evidence 2x10mg/kg nasopharyngitis 25% (placebo 35.7%) headache 21.4% (placebo 7.1%) dizziness 14.3% (placebo 0%) NCT00809614 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
secukinumab
show 17 more results
show 10 more results
show 10 more results
show 10 more results
show 2 more results
show 12 more results
show 13 more results
+ 98 further endpoints in the CSV export.
Psoriasis
Shared mechanism: IL-17 · full Psoriasis pipeline
secukinumab · Cosentyx
Marketed by Novartis
NCT01358578 · Phase 3 · completed
This was a large, randomized, quadruple-blind trial with both placebo and active etanercept comparator groups, enrolling 1,306 participants. The clinical primary endpoints at week 12 were met in the favorable direction based on the reported counts: PASI 75 and IGA 0/1 responses were achieved by large majorities of secukinumab-treated participants compared with very few placebo-treated participants, although formal statistical analyses are not posted in the registry.
Next expected readout: December 2027 · NCT04239859 (registry estimate)
Reported efficacy
Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks); Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12 (12 wks): Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%) (met)
Result source: NCT01358578
vunakizumab
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT04839016 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled Phase 3 trial randomized 690 patients with moderate-to-severe plaque psoriasis 2:1 to vunakizumab 240 mg or placebo. The co-primary endpoints were PASI 90 and sPGA 0/1 at week 12. PASI 90 was reached by 76.8% of patients on vunakizumab and 0.9% on placebo, and sPGA 0/1 by 71.8% and 0.4% (both two-sided P < .0001), so both co-primary endpoints were met. The registry record still shows its 2021 estimated enrollment of 660 and has no posted results; the figures come from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025).
Caveat: this result is taken from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025, PMID 39332633); the ClinicalTrials.gov record (status unknown) has no posted results.
Next expected readout: March 2027 · NCT06779097 (registry estimate)
Reported efficacy
Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90) at Week 12; sPGA of 0 or 1 response at Week 12: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). (met)
Result source: NCT04839016
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | secukinumab | vunakizumab |
|---|---|---|
| PASI 75 | 77.1% vs 4.9%+72.2 vs placeboNCT0135857827 other results
| —Trial running · NCT06833307 |
| PASI 90 | 79% vs 57.3%vs UstekinumabNCT0207498223 other results
| —Trial running · NCT06833307 |
| PASI 100 | 23.5% vs 0%+23.5 vs placeboNCT0226713513 other results
| —Trial running · NCT06833307 |
| sPGA 0/1 | 62.5% vs 2.8%+59.7 vs placeboNCT013585783 other results
| —Trial running · NCT06833307 |
| DLQI, change | -13.2 vs -2.0−11.2 vs placeboNCT035898851 other result
| —Trial running · NCT06833307 |
PASI 75
- secukinumab
- 77.1% vs 4.9%+72.2 vs placeboNCT01358578
27 other results
- 81.6% vs 4.5% NCT01365455
- 93.4% vs 4.4% NCT03066609
- 67% vs 4.9% NCT01358578
- 71.6% vs 4.5% NCT01365455
- 75.9% vs 0% NCT01555125
- 82.4% vs 4.4% NCT03066609
- 95.1% vs 10% NCT03589885
- 69.5% vs 0% NCT01555125
- 88.9% vs 1.4% NCT02748863
- 80% vs 14.6% NCT02471144
- 77.5% vs 14.6% NCT02471144
- 64.7% vs 2% NCT02267135
- 92% vs 79.9% NCT02826603
- 77.1% vs 44% NCT01358578
- 88% vs 74.1% NCT02826603
- 40.2% vs 16.3% NCT02826603
- 49.7% vs 20.6% NCT02074982
- 67% vs 44% NCT01358578
- 88.6% vs 27.4% NCT02474082
- 87.6% vs 21.1% NCT02474082
- 80% vs 8.4% NCT02474082
- 69.5% vs 2.1% NCT02474082
- 47.6% vs 1.1% NCT02474082
- 24.8% vs 0% NCT02474082
- 5.7% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 84.8% vs 0% NCT02690701
- vunakizumab
- —Trial running · NCT06833307
PASI 90
- secukinumab
- 79% vs 57.3%vs UstekinumabNCT02074982
23 other results
- 66.5% vs 48% NCT02826603
- 54.2% vs 1.5% NCT01358578
- 59.2% vs 1.2% NCT01365455
- 77.2% vs 1.5% NCT03066609
- 41.9% vs 1.5% NCT01358578
- 39.1% vs 1.2% NCT01365455
- 62.5% vs 1.5% NCT03066609
- 75.6% vs 5% NCT03589885
- 47.1% vs 0% NCT02267135
- 66.7% vs 1.4% NCT02748863
- 72.5% vs 2.4% NCT02471144
- 67.5% vs 2.4% NCT02471144
- 76.9% vs 54.2% NCT02826603
- 68.6% vs 8.4% NCT02474082
- 63.8% vs 2.1% NCT02474082
- 46.7% vs 1.1% NCT02474082
- 32.4% vs 0% NCT02474082
- 17.1% vs 0% NCT02474082
- 2.9% vs 0% NCT02474082
- 1.9% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 53.7% vs 0% NCT03055494
- 73.9% vs 0% NCT02690701
- vunakizumab
- —Trial running · NCT06833307
PASI 100
- secukinumab
- 23.5% vs 0%+23.5 vs placeboNCT02267135
13 other results
- 38.9% vs 0% NCT02748863
- 36.6% vs 0% NCT02748863
- 45.5% vs 26.6% NCT02826603
- 38.2% vs 20.1% NCT02826603
- 37.1% vs 0% NCT02474082
- 28.6% vs 0% NCT02474082
- 15.2% vs 0% NCT02474082
- 7.6% vs 0% NCT02474082
- 3.8% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 0% vs 0% NCT02474082
- 37% vs 0% NCT02690701
- vunakizumab
- —Trial running · NCT06833307
sPGA 0/1
- secukinumab
- 62.5% vs 2.8%+59.7 vs placeboNCT01358578
3 other results
- 51.1% vs 2.8% NCT01358578
- 62.5% vs 27.2% NCT01358578
- 51.1% vs 27.2% NCT01358578
- vunakizumab
- —Trial running · NCT06833307
DLQI, change
- secukinumab
- -13.2 vs -2.0−11.2 vs placeboNCT03589885
1 other result
- -9.4 vs -0.5 NCT02690701
- vunakizumab
- —Trial running · NCT06833307
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. secukinumab: 4 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | secukinumab |
|---|---|
| Dropout rate | 4.6%300mga NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 95 more results—300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 3.7%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 2.9%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 6.1%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 5.1%300 mg NCT01555125 · Phase 3 —300 mg NCT01555125 · Phase 3 1.7%150 mg NCT01555125 · Phase 3 —150 mg NCT01555125 · Phase 3 0%300 mg NCT01636687 · Phase 3 —300 mg NCT01636687 · Phase 3 4.9%150 mg NCT01636687 · Phase 3 —150 mg NCT01636687 · Phase 3 —300 mg NCT02267135 · Phase 3 2%Secukinumab NCT02267135 · Phase 3 —300 mg (2x1mL PFS) NCT02748863 · Phase 3 —300 mg (2mL PFS) NCT02748863 · Phase 3 0%2 mL PFS NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 2.8%2 x 1 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 —300 mg NCT03589885 · Phase 3 0% NCT04717466 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 18.5%300 mg NCT03055494 · Phase 4 · registry result, not featured evidence 13.3% NCT02592018 · Phase 4 · registry result, not featured evidence —300 mg NCT02690701 · Phase 4 · registry result, not featured evidence 4.3%Secukinumab NCT02690701 · Phase 4 · registry result, not featured evidence 0%300 mg NCT02547714 · Phase 4 · registry result, not featured evidence —Entire Period - Secukinumab (AIN45 NCT02547714 · Phase 4 · registry result, not featured evidence —Induction Period - Secukinumab (AI NCT02547714 · Phase 4 · registry result, not featured evidence 14.3%AIN457 High Dose NCT03668613 · Phase 3 · registry result, not featured evidence 26.2%AIN457 Low Dose NCT03668613 · Phase 3 · registry result, not featured evidence 10.3%300 mg every 2 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 13.3%300 mg every 4 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 9.7%300 mg every 4 weeks (up-titration) NCT03504852 · Phase 3 · registry result, not featured evidence —300 mg NCT03066609 · Phase 3 · registry result, not featured evidence 0.7%300 mg NCT03066609 · Phase 3 · registry result, not featured evidence —150 mg NCT03066609 · Phase 3 · registry result, not featured evidence 1.5%150 mg NCT03066609 · Phase 3 · registry result, not featured evidence —300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 11.1%300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 4.7%300 mg NCT01544595 · Phase 3 · registry result, not featured evidence 13%150 mg NCT01544595 · Phase 3 · registry result, not featured evidence 7.7%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 7%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 19%300 mg NCT02008890 · Phase 3 · registry result, not featured evidence —300 mg NCT02008890 · Phase 3 · registry result, not featured evidence 18.8%150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 1 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 2 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 3 NCT02409667 · Phase 3 · registry result, not featured evidence 25%300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 48.5%300 mg open-label NCT01640951 · Phase 3 · registry result, not featured evidence 78.3%300 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 16.1%300 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 20%150 mg fixed interval then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 13.7%150 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 81.8%150 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 59.7%150 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg NCT02595970 · Phase 3 · registry result, not featured evidence 16.7%Single Arm Secukinumab NCT02595970 · Phase 3 · registry result, not featured evidence 1.5%300 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 6%150 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 7.2%300 mg NCT01806597 · Phase 3 · registry result, not featured evidence 7.4%150 mg NCT01806597 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 3%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence — NCT02362789 · Phase 3 · registry result, not featured evidence 10.1%300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 11.2%150 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg NCT01961609 · Phase 3 · registry result, not featured evidence 15.1%300 mg NCT02074982 · Phase 3 · registry result, not featured evidence 5.7% NCT02474082 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 1.2%300mga NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 95 more results—300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 0.6%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 1.2%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 2%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 1.7%300 mg NCT01555125 · Phase 3 —300 mg NCT01555125 · Phase 3 0%150 mg NCT01555125 · Phase 3 —150 mg NCT01555125 · Phase 3 0%300 mg NCT01636687 · Phase 3 —300 mg NCT01636687 · Phase 3 1.6%150 mg NCT01636687 · Phase 3 —150 mg NCT01636687 · Phase 3 —300 mg NCT02267135 · Phase 3 —Secukinumab NCT02267135 · Phase 3 —300 mg (2x1mL PFS) NCT02748863 · Phase 3 —300 mg (2mL PFS) NCT02748863 · Phase 3 0%2 mL PFS NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 1.4%2 x 1 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 —300 mg NCT03589885 · Phase 3 — NCT04717466 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence —300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03055494 · Phase 4 · registry result, not featured evidence 6.7% NCT02592018 · Phase 4 · registry result, not featured evidence —300 mg NCT02690701 · Phase 4 · registry result, not featured evidence 4.3%Secukinumab NCT02690701 · Phase 4 · registry result, not featured evidence —300 mg NCT02547714 · Phase 4 · registry result, not featured evidence —Entire Period - Secukinumab (AIN45 NCT02547714 · Phase 4 · registry result, not featured evidence —Induction Period - Secukinumab (AI NCT02547714 · Phase 4 · registry result, not featured evidence 4.8%AIN457 High Dose NCT03668613 · Phase 3 · registry result, not featured evidence 2.4%AIN457 Low Dose NCT03668613 · Phase 3 · registry result, not featured evidence 2.4%300 mg every 2 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 5.9%300 mg every 4 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 6.5%300 mg every 4 weeks (up-titration) NCT03504852 · Phase 3 · registry result, not featured evidence —300 mg NCT03066609 · Phase 3 · registry result, not featured evidence 0.7%300 mg NCT03066609 · Phase 3 · registry result, not featured evidence —150 mg NCT03066609 · Phase 3 · registry result, not featured evidence 1.5%150 mg NCT03066609 · Phase 3 · registry result, not featured evidence —300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 3.1%300 mg NCT02826603 · Phase 3 · registry result, not featured evidence 0.6%300 mg NCT01544595 · Phase 3 · registry result, not featured evidence 1%150 mg NCT01544595 · Phase 3 · registry result, not featured evidence 3.7%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 3.8%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 10.1%300 mg NCT02008890 · Phase 3 · registry result, not featured evidence —300 mg NCT02008890 · Phase 3 · registry result, not featured evidence 7.5%150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —150 mg NCT02008890 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 1 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 2 NCT02409667 · Phase 3 · registry result, not featured evidence —Treatment Period 2: Group 3 NCT02409667 · Phase 3 · registry result, not featured evidence 6%300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 9.1%300 mg open-label NCT01640951 · Phase 3 · registry result, not featured evidence 18.3%300 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 0.9%300 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 4%150 mg fixed interval then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 1.1%150 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 10.9%150 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence 10.4%150 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg NCT02595970 · Phase 3 · registry result, not featured evidence 4.2%Single Arm Secukinumab NCT02595970 · Phase 3 · registry result, not featured evidence 0%300 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 3%150 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled 1.4%300 mg NCT01806597 · Phase 3 · registry result, not featured evidence 1.5%150 mg NCT01806597 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 1%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence — NCT02362789 · Phase 3 · registry result, not featured evidence 2.5%300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 4.3%150 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg NCT01961609 · Phase 3 · registry result, not featured evidence 4.5%300 mg NCT02074982 · Phase 3 · registry result, not featured evidence 1.9% NCT02474082 · Phase 3 · registry result, not featured evidence |
| Serious AEs | —300mga NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 95 more results6.4%300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 1.2%300mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 5.5%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 2.1%150mg NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 6.9%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 5.4%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 2.1%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 2.4%300 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 6.1%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 5.4%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 1.7%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 1.6%150 mg NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 —300 mg NCT01555125 · Phase 3 5.1%300 mg NCT01555125 · Phase 3 —150 mg NCT01555125 · Phase 3 1.7%150 mg NCT01555125 · Phase 3 —300 mg NCT01636687 · Phase 3 1.7%300 mg NCT01636687 · Phase 3 —150 mg NCT01636687 · Phase 3 4.9%150 mg NCT01636687 · Phase 3 0%300 mg NCT02267135 · Phase 3 —Secukinumab NCT02267135 · Phase 3 1.4%300 mg (2x1mL PFS) NCT02748863 · Phase 3 0%300 mg (2mL PFS) NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 —2 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 —2 x 1 mL PFS NCT02748863 · Phase 3 2.4%300 mg NCT03589885 · Phase 3 10% NCT04717466 · Phase 4 · registry result, not featured evidence 5.4%300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03020199 · Phase 4 · registry result, not featured evidence 1.9%300 mg NCT03055494 · Phase 4 · registry result, not featured evidence 6.7% NCT02592018 · Phase 4 · registry result, not featured evidence 10.9%300 mg NCT02690701 · Phase 4 · registry result, not featured evidence —Secukinumab NCT02690701 · Phase 4 · registry result, not featured evidence —300 mg NCT02547714 · Phase 4 · registry result, not featured evidence 0%Entire Period - Secukinumab (AIN45 NCT02547714 · Phase 4 · registry result, not featured evidence 0%Induction Period - Secukinumab (AI NCT02547714 · Phase 4 · registry result, not featured evidence 4.8%AIN457 High Dose NCT03668613 · Phase 3 · registry result, not featured evidence 9.5%AIN457 Low Dose NCT03668613 · Phase 3 · registry result, not featured evidence 8.5%300 mg every 2 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 13.4%300 mg every 4 weeks NCT03504852 · Phase 3 · registry result, not featured evidence 12.9%300 mg every 4 weeks (up-titration) NCT03504852 · Phase 3 · registry result, not featured evidence 3.3%300 mg NCT03066609 · Phase 3 · registry result, not featured evidence —300 mg NCT03066609 · Phase 3 · registry result, not featured evidence 3.7%150 mg NCT03066609 · Phase 3 · registry result, not featured evidence —150 mg NCT03066609 · Phase 3 · registry result, not featured evidence 5.3%300 mg NCT02826603 · Phase 3 · registry result, not featured evidence —300 mg NCT02826603 · Phase 3 · registry result, not featured evidence —300 mg NCT01544595 · Phase 3 · registry result, not featured evidence —150 mg NCT01544595 · Phase 3 · registry result, not featured evidence 8.5%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence 5.4%300 mg NCT02394561 · Phase 3 · registry result, not featured evidence —300 mg NCT02008890 · Phase 3 · registry result, not featured evidence 16.5%300 mg NCT02008890 · Phase 3 · registry result, not featured evidence —150 mg NCT02008890 · Phase 3 · registry result, not featured evidence 11.3%150 mg NCT02008890 · Phase 3 · registry result, not featured evidence 3.9%Treatment Period 2: Group 1 NCT02409667 · Phase 3 · registry result, not featured evidence 3.8%Treatment Period 2: Group 2 NCT02409667 · Phase 3 · registry result, not featured evidence 3.5%Treatment Period 2: Group 3 NCT02409667 · Phase 3 · registry result, not featured evidence —300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg open-label NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence —300 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg fixed interval then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg as needed then 300 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg as needed NCT01640951 · Phase 3 · registry result, not featured evidence —150 mg fixed interval NCT01640951 · Phase 3 · registry result, not featured evidence 10.8%300 mg NCT02595970 · Phase 3 · registry result, not featured evidence —Single Arm Secukinumab NCT02595970 · Phase 3 · registry result, not featured evidence —300 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled —150 mg NCT01807520 · Phase 3 · registry result, not featured evidence · pooled —300 mg NCT01806597 · Phase 3 · registry result, not featured evidence —150 mg NCT01806597 · Phase 3 · registry result, not featured evidence —300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 2.5%300 mg s.c. (2-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 4.9%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence —300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 4.1%300 mg s.c. (4-weekly) NCT02474069 · Phase 3 · registry result, not featured evidence 4.8% NCT02362789 · Phase 3 · registry result, not featured evidence —300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 13.4%300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence —150 mg - 300 mg NCT01961609 · Phase 3 · registry result, not featured evidence 12.2%150 mg NCT01961609 · Phase 3 · registry result, not featured evidence 12.2%300 mg NCT02074982 · Phase 3 · registry result, not featured evidence 3.8% NCT02474082 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 300mga nasopharyngitis 27.9% (placebo 8%) headache 14.4% (placebo 7.3%) diarrhoea 10.4% (placebo 2.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 show 51 more results300mg nasopharyngitis 10.7% (placebo 8%) headache 9.2% (placebo 7.3%) diarrhoea 5.2% (placebo 2.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 150mg nasopharyngitis 25.1% (placebo 8%) headache 10.4% (placebo 7.3%) diarrhoea 9.2% (placebo 2.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 150mg nasopharyngitis 13.5% (placebo 8%) headache 4.9% (placebo 7.3%) arthralgia 4.3% (placebo 3.1%) NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg nasopharyngitis 18.4% (placebo 8.1%) upper respiratory tract infection 10.6% (placebo 0.8%) headache 9% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg nasopharyngitis 16.3% (placebo 8.1%) upper respiratory tract infection 9.2% (placebo 0.8%) headache 8.6% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg arthralgia 2.1% (placebo 3.2%) blood creatinine increased 2.1% (placebo 0.4%) eczema 2.1% (placebo 0%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg nasopharyngitis 9% (placebo 8.1%) headache 4.9% (placebo 4%) pruritus 4.5% (placebo 2.4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg nasopharyngitis 21.6% (placebo 8.1%) upper respiratory tract infection 11.4% (placebo 0.8%) headache 7.8% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg nasopharyngitis 19.5% (placebo 8.1%) upper respiratory tract infection 10.2% (placebo 0.8%) headache 6.8% (placebo 4%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg psoriasis 3.4% (placebo 3.2%) psoriatic arthropathy 3.4% (placebo 1.6%) influenza 1.7% (placebo 1.2%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 150 mg nasopharyngitis 9.4% (placebo 8.1%) headache 5.3% (placebo 4%) oropharyngeal pain 4.1% (placebo 1.2%) NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 300 mg diarrhoea 8.5% (placebo 1.7%) back pain 5.1% (placebo 0%) nasopharyngitis 5.1% (placebo 8.5%) NCT01555125 · Phase 3 150 mg headache 6.8% (placebo 6.8%) diarrhoea 5.1% (placebo 1.7%) nasopharyngitis 5.1% (placebo 8.5%) NCT01555125 · Phase 3 300 mg nasopharyngitis 31.7% (placebo 14.8%) pruritus 6.7% (placebo 3.3%) cough 5% (placebo 3.3%) NCT01636687 · Phase 3 150 mg nasopharyngitis 23% (placebo 14.8%) headache 8.2% (placebo 4.9%) hypertension 4.9% (placebo 6.6%) NCT01636687 · Phase 3 300 mg dermatitis contact 5.9% (placebo 3.9%) nasopharyngitis 5.9% (placebo 2%) diarrhoea 3.9% (placebo 3.9%) NCT02267135 · Phase 3 300 mg (2x1mL PFS) nasopharyngitis 11.3% (placebo 11.3%) headache 8.5% (placebo 4.2%) back pain 4.2% (placebo 2.8%) NCT02748863 · Phase 3 300 mg (2mL PFS) nasopharyngitis 9.7% (placebo 11.3%) headache 8.3% (placebo 4.2%) pruritus 6.9% (placebo 4.2%) NCT02748863 · Phase 3 300 mg nasopharyngitis 14.6% (placebo 0%) hypertension 9.8% (placebo 0%) influenza like illness 7.3% (placebo 2.5%) NCT03589885 · Phase 3 300 mg headache 9.8% nasopharyngitis 9.8% upper respiratory tract infection 7.1% NCT03020199 · Phase 4 · registry result, not featured evidence 300 mg arthralgia 5.7% nasopharyngitis 3.4% headache 1.1% NCT03020199 · Phase 4 · registry result, not featured evidence 300 mg nasopharyngitis 18.5% upper respiratory tract infection 13% back pain 7.4% NCT03055494 · Phase 4 · registry result, not featured evidence upper respiratory infection 60% cough 20% diarrhea 13.3% NCT02592018 · Phase 4 · registry result, not featured evidence 300 mg nasopharyngitis 19.6% upper respiratory tract infection 13% arthralgia 10.9% NCT02690701 · Phase 4 · registry result, not featured evidence nasopharyngitis 20.6% dermatitis contact 5.9% hypertension 5.9% NCT02547714 · Phase 4 · registry result, not featured evidence nasopharyngitis 11.8% alopecia 2.9% dermatitis contact 2.9% NCT02547714 · Phase 4 · registry result, not featured evidence covid-19 21.4% nasopharyngitis 16.7% viral upper respiratory tract infection 16.7% NCT03668613 · Phase 3 · registry result, not featured evidence nasopharyngitis 31% covid-19 26.2% acne 16.7% NCT03668613 · Phase 3 · registry result, not featured evidence 300 mg every 2 weeks nasopharyngitis 19.4% upper respiratory tract infection 7.3% headache 6.7% NCT03504852 · Phase 3 · registry result, not featured evidence 300 mg every 4 weeks nasopharyngitis 16.4% upper respiratory tract infection 6.7% oropharyngeal pain 5.2% NCT03504852 · Phase 3 · registry result, not featured evidence 300 mg every 4 weeks (up-titration) nasopharyngitis 16.1% intertrigo 9.7% neutrophil count decreased 9.7% NCT03504852 · Phase 3 · registry result, not featured evidence 300 mg upper respiratory tract infection 24.6% (placebo 9.6%) hyperuricaemia 20.6% (placebo 12.6%) nasopharyngitis 16.2% (placebo 3.7%) NCT03066609 · Phase 3 · registry result, not featured evidence 150 mg upper respiratory tract infection 30.1% (placebo 9.6%) hyperuricaemia 18.4% (placebo 12.6%) influenza 12.5% (placebo 3%) NCT03066609 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 10% upper respiratory tract infection 8.9% diarrhoea 4.7% NCT02826603 · Phase 3 · registry result, not featured evidence 300 mg viral upper respiratory tract infection 39.2% (placebo 15.4%) pustular psoriasis 20.3% (placebo 5.1%) headache 15.2% (placebo 12.8%) NCT02008890 · Phase 3 · registry result, not featured evidence 150 mg pustular psoriasis 23.8% (placebo 5.1%) viral upper respiratory tract infection 21.3% (placebo 15.4%) headache 8.8% (placebo 12.8%) NCT02008890 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 14.6% (placebo 23.7%) headache 4.8% (placebo 1.1%) back pain 2.8% (placebo 1.1%) NCT02409667 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 14.4% (placebo 23.7%) back pain 4.2% (placebo 1.1%) headache 4.1% (placebo 1.1%) NCT02409667 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20.2% (placebo 23.7%) psoriasis 9.6% (placebo 8.6%) upper respiratory tract infection 6.1% (placebo 5.4%) NCT02409667 · Phase 3 · registry result, not featured evidence 300 mg back pain 10.8% nasopharyngitis 10.8% diarrhoea 10% NCT02595970 · Phase 3 · registry result, not featured evidence 300 mg s.c. (2-weekly) nasopharyngitis 16.6% headache 3.1% hypertension 2.5% NCT02474069 · Phase 3 · registry result, not featured evidence 300 mg s.c. (4-weekly) nasopharyngitis 14.2% headache 3.1% arthralgia 2.5% NCT02474069 · Phase 3 · registry result, not featured evidence 300 mg s.c. (4-weekly) nasopharyngitis 21.8% headache 7.8% diarrhoea 4.4% NCT02474069 · Phase 3 · registry result, not featured evidence nasopharyngitis 28.6% (placebo 28.9%) headache 7.1% (placebo 2.6%) hypertension 4.8% (placebo 5.3%) NCT02362789 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 29.1% oropharyngeal pain 16.2% headache 15.6% NCT01961609 · Phase 3 · registry result, not featured evidence 150 mg headache 23.5% nasopharyngitis 23.5% psoriasis 13% NCT01961609 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 28.7% headache 14.9% upper respiratory tract infection 12.5% NCT02074982 · Phase 3 · registry result, not featured evidence nasopharyngitis 51.4% headache 14.3% diarrhoea 6.7% NCT02474082 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 78 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
secukinumab
show 27 more results
show 3 more results
show 23 more results
show 1 more result
show 1 more result
show 3 more results
show 22 more results
show 11 more results
show 51 more results
show 1 more result
show 9 more results
show 17 more results
+ 167 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: secukinumab's landscape · vunakizumab's landscape